Common Contracts
4 similar Underwriting Agreement contracts by Aeglea BioTherapeutics, Inc., Cibus, Inc., Leap Therapeutics, Inc., Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. 10,638,476 Shares of Common Stock And Pre-Funded Warrants to Purchase 10,638,524 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • May 16th, 2024 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
CIBUS, INC. 2,106,723 Shares of Class A Common Stock and Pre-Funded Warrants to Purchase 50,000 Shares of Class A Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2023 • Cibus, Inc. • Agricultural chemicals • New York
Cibus, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) (i) an aggregate of 2,106,723 shares (the “Shares”) of the Class A common stock, par value $0.0001 per share, of the Company (“Common Stock”) and (ii) pre-funded warrants to purchase an aggregate of 50,000 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”, and together with the Shares, the “Securities”). The shares of Common Stock issuable upon exercise of the Warrants are hereinafter referred to as the “Warrant Shares”.
22,828,072 Shares of Common Stock Pre-Funded Warrants to Purchase 8,771,928 Shares of Common Stock Leap Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • September 22nd, 2021 • Leap Therapeutics, Inc. • Pharmaceutical preparations • New York
Leap Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,828,072 shares (the “Firm Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company, and pre-funded warrants to purchase up to an aggregate of 8,771,928 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”). The Company has also granted to the several Underwriters an option to purchase up to 4,740,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and the Warrants are herein referred to as the “Firm Securities.” The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Shares.” The Shares and the Warrants are herein referred to as the “Securities.” The shares of Common Stock issuabl
AEGLEA BIOTHERAPEUTICS, INC. 11,652,830 Shares of Common Stock, par value $0.0001 Pre-Funded Warrants to Purchase 13,610,328 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 28th, 2020 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,652,830 shares (the “Underwritten Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), pre-funded warrants to purchase an aggregate of 13,610,328 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”) and, at the option of the Underwriters, up to an additional 3,789,473 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The Shares and Warrants are herein referred to as the “Securities.” The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant
